KLOW peptide logs four research arms on one instrument panel, the literature read channel by channel

The short version

KLOW peptide is not a single molecule. It is four separate research peptides — KPV, GHK-Cu, BPC-157 and TB-500 — co-dissolved in one lyophilized vial at fixed amounts: GHK-Cu (50 mg), BPC-157 (10 mg), TB-500 (10 mg) and KPV (10 mg), for an 80 mg total. None of the four is FDA-approved for human use. The blend itself has never been tested in a controlled study — every claim about what KLOW does is an extrapolation from single-ingredient research conducted on each peptide alone, mostly in cells and rodents.

This site is a research index. It logs what the component studies have actually measured — tissue repair, gut inflammation, skin and matrix changes, wound healing — attributed to the specific peptide the study tested. Where no data exists for the combination (which is everywhere), that is logged as a null. The KLOW effects page covers what people report in research-use communities, clearly labeled as anecdotal. The honest summary: four well-studied ingredients, zero combination trial, one pharmacokinetic mismatch baked in.

KLOW

KLOW peptide is a co-formulated research blend of four chemically distinct peptides. The canonical vial carries 80 mg total at a 50/10/10/10 mass ratio: GHK-Cu is the dominant arm at ~62.5% by mass; BPC-157, TB-500 and KPV each contribute 10 mg. The four components are co-dissolved, not chemically bonded — they remain separate molecules throughout. No single CAS number or unified pharmacopoeial monograph exists for the KLOW mixture.

Each arm occupies a distinct node of the tissue-repair signaling network. KPV (Lys-Pro-Val, CAS 67727-97-3, MW 342.44 Da) is the anti-inflammatory tripeptide, transported into gut epithelial cells and macrophages via the PepT1 transporter (SLC15A1, Km ~160 microM) ^[3]. GHK-Cu (Gly-His-Lys copper complex, CAS 89030-95-5, MW 402.92 Da) is the matrix-and-copper arm, modulating expression of roughly 31% of assayed protein-coding genes toward tissue repair at low-nanomolar concentrations ^[5]. BPC-157 (15-amino-acid gastric peptide, CAS 137525-51-0, MW 1419.53 Da) drives the VEGFR2/PI3K/Akt/eNOS angiogenic axis and has accelerated tendon healing in rat models ^[2]. TB-500 (Ac-LKKTETQ, MW 889.02 Da) is the cytoskeletal arm, sequestering G-actin via the LKKTET motif — though the most cited efficacy data are for full-length native thymosin beta-4 (43 amino acids), not the short fragment ^[7].

KLOW blend

The KLOW peptide blend rationale is mechanistic complementarity: KPV addresses cytokine-driven inflammation at the transcription level; GHK-Cu addresses extracellular-matrix synthesis and redox protection; BPC-157 addresses vascular supply and angiogenesis; TB-500 addresses cytoskeletal dynamics and cell migration. Together they are said to cover four distinct steps of one tissue-repair cascade.

The honest gap: no controlled in-vivo or human study has tested the four-peptide KLOW blend against any comparator. The argument for the stack is mechanistic, not clinical. Additionally, a pharmacokinetic mismatch is built in — the two tripeptides (KPV, GHK-Cu) clear far faster than BPC-157, and the TB-500 fragment has different pharmacokinetics from native thymosin beta-4, so a single co-dissolved dose cannot keep all four components at matched tissue exposures.

For the full KLOW stack breakdown — component CAS numbers, molecular weights, vial shares and mechanisms — see the blend-components page.

KLOW peptide blend — what the component research has measured

Across the component literature, the most-cited results per arm are:

KPV arm ^[3][9]: At 10 nM in vitro, KPV reduced NF-kB and MAPK activation and pro-inflammatory cytokine secretion (TNF-alpha, IL-6, IL-1beta) in human intestinal epithelial cells and T cells. Oral KPV in mouse colitis (DSS and TNBS models) reduced colonic inflammation and myeloperoxidase activity. The PepT1 transporter is upregulated in inflamed gut tissue — favoring KPV uptake at the sites where inflammation is active ^[3].

GHK-Cu arm ^[4][5]: Topical GHK-Cu increased collagen production in 70% of treated women versus 50% for vitamin C and 40% for retinoic acid in one reviewed clinical dataset ^[4]. At 1-10 nM, GHK modulated expression of approximately 31% of human protein-coding genes (at ≥50% change), with strongest effects on extracellular-matrix remodeling, antioxidant defense and DNA-repair gene sets ^[5]. Plasma GHK levels decline from about 200 ng/mL at age 20 to about 80 ng/mL by age 60 ^[4].

BPC-157 arm ^[2][8]: BPC 157 accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional and histologic measures, and stimulated tendocyte outgrowth in vitro ^[2]. In gastric-ulcer models, 400-800 ng/kg inhibited ulcer formation at 45.7-65.6% vs controls ^[8]. A 2025 IV safety pilot — two adults, up to 20 mg IV — reported no adverse events and no measurable changes in cardiac, hepatic, renal or metabolic markers ^[6].

TB-500 arm ^[1]: In a rat full-thickness wound model, native thymosin beta-4 increased re-epithelialization by 42% at 4 days and 61% at 7 days versus saline, increased wound contraction (≥11% by day 7) and raised collagen deposition; as little as 10 pg stimulated keratinocyte migration 2–3-fold ^[1]. These results are for full-length Tbeta4 — the TB-500 fragment shares the LKKTET actin-binding motif but the data do not automatically transfer ^[7].

What this site does not do: link to the KLOW effects page reports from the community (anecdotal, not clinical) alongside this component evidence so a reader has both layers clearly labeled.

KLOW peptide buy — framing and status

KLOW peptide circulates in the research-chemical market as a lyophilized research vial. This site does not sell product and does not direct readers to vendors. The 'shop' in shopklow.com names this as a research index of the KLOW literature, not a storefront.

For any researcher working with KLOW: the KLOW references page lists the full component citation record. The dosage page logs the research-context doses used in the component studies — none of which constitutes a validated human protocol for the blend.